International Journal of Gerontology
Volume 1, Issue 2 , Pages 98-102, June 2007

Current Trends in Treating Cervical Cancer

  • Kung-Liahng Wang

      Affiliations

    • Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
    • National Taipei College of Nursing, Taipei, Taiwan
    • Mackay Medicine, Nursing and Management College, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Kung-Liahng Wang, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei 104, Taiwan

Accepted 20 March 2007.

Article Outline

SUMMARY 

Cervical cancer is the most common gynecologic malignancy worldwide. Squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma are the three major histologic types, and this cancer develops slowly and locally. Radical hysterectomy plus pelvic lymph node dissection or concurrent chemoradiation therapy (CCRT) is the standard treatment when the disease is at an early stage. CCRT remains the standard for locally advanced disease, and systemic chemotherapy plays a major role in disease with distant metastases. In recent decades, some new trends in treating this cancer have been discussed and applied. A series of clinical trials and retrospective studies support a more conservative surgical treatment in early-stage disease. Sentinel lymph node mapping is used to decrease the morbidities after nodal dissection. Some new concurrent chemotherapeutic agents and schedules have been developed to replace the traditional cisplatin-base agents in order to decrease the toxicity during CCRT. Consolidation chemotherapy after CCRT can help improve the outcome. Neoadjuvant chemotherapy plus radiotherapy has revealed itself as the potential application as part of a new therapeutic trend in treating locally advanced cervical cancer patients. In the Gynecologic Oncology Group (GOG) phase III trial (GOG-179), cisplatin plus topotecan was proved to prolong the patients' survival time. Vaccines, both prophylactic and therapeutic, will be the trend in the future. This article intends to review recent reports and update the available information relating to the current trends in the management of cervical cancer.

Key Words:  cervical cancer , chemotherapy , concurrent chemoradiation therapy (CCRT) , surgery , vaccine

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Taiwan Health and National Health Insurance Annual Statistics Information Service, 28 April, 2004. Available at http://www.doh.gov.tw/statistic/index.htm
  2. Walboomers JM , Jacobs MV , Manos MM , Bosch FX , Kummer JA , Shah KV , et al.   Human papillomavirus is a necessary cause of invasive cervical cancer worldwide . J Pathol . 1999;189:12–19
  3. Ostor AG . Studies on 200 cases of early squamous cell carcinoma of the cervix . Int J Gynecol Pathol . 1993;12:193–207
  4. Hacker NF . Chapter 9: Cervical cancer . In:  Berek JS ,  Hacker NF editor. Practical Gynecologic Oncology . 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2000;p. 357
  5. Yang YC , Chang CL . Modified radical hysterectomy for early Ib cervical cancer . Gynecol Oncol . 1999;74:241–244
  6. Keys HM , Bundy BN , Stehman FB , Muderspach LI , Chafe WE , Suggs CL , et al.   Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma . N Engl J Med . 1999;340:1154–1161
  7. Morris M , Eifel PJ , Lu J , Grigsby PW , Levenback C , Stevens RE , et al.   Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer . N Engl J Med . 1999;340:1137–1143
  8. Chen SW , Liang JA , Hung YC , Yeh LS , Chang WC , Lin WC , et al.   Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications . Int J Radiat Oncol Biol Phys . 2006;66:1370–1377
  9. Ikushima H , Osaki K , Furutani S , Yamashita K , Kawanaka T , Kishida Y , et al.   Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin . Radiat Med . 2006;24:115–121
  10. Einstein MH , Novetsky AP , Garg M , Hailpern SM , Huang GS , Glueck A , et al.   Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer . Cancer . 2007;109:48–53
  11. Candelaria M , Garcia-Arias A , Cetina L , Duenas-Gonzalez A . Radiosensitizers in cervical cancer. Cisplatin and beyond . Radiat Oncol . 2006;1:15
  12. Wydra D , Sawicki S , Wojtylak S , Bandurski T , Emerich J . Sentinel node identification in cervical cancer patients undergoing transperitoneal radical hysterectomy: a study of 100 cases . Int J Gynecol Cancer . 2006;16:649–654
  13. Vrdoljak E , Omrcen T , Novakovic ZS , Jelavic TB , Prskalo T , Hrepic D , et al.   Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix—final results of a prospective phase II-study . Gynecol Oncol . 2006;103:494–499
  14. Kim DS , Moon H , Kim KT , Hwang YY , Cho SH , Kim SR . Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumors . Gynecol Oncol . 1989;33:225–230
  15. Eddy GL , Manetta A , Alvarez RD , Williams L , Creasman WT . Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage Ib bulky cervical cancer: a gynecologic oncology group pilot study . Gynecol Oncol . 1995;57:412–416
  16. Benedetti Panici P , Scambia G , Greggi S , Di Roberto P , Baiocchi G , Mancuso S . Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study . Obstet Gynecol . 1988;71:344–348
  17. Kumar L , Biswal BM , Kumar S . Randomized phase III study of neoadjuvant chemotherapy + radiotherapy vs. radiotherapy alone in locally advanced cervical cancer . Proc Am Soc Clin Oncol . 1994;13:A819
  18. Tierney J  Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration . Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials . Eur J Cancer . 2003;39:2470–2486
  19. Sardi JE , Boixadera MA , Sardi JJ . Neoadjuvant chemotherapy in cervical cancer: a new trend . Curr Opin Obstet Gynecol . 2005;17:43–47
  20. Thigpen JT , Shingleton H , Homesley H , Lagasse L , Blessing J . Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group . Cancer . 1981;48:899–903
  21. Stehman FB , Blessing JA , McGehee R , Barrett RJ . A phase II evaluation of mitolactol (NSC #104800) in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study . J Clin Oncol . 1989;7:1892–1895
  22. McGuire WP , Blessing JA , Moore D , Lentz SS , Photopulos G . Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study . J Clin Oncol . 1996;14:792–795
  23. Burnett AF , Roman LD , Garcia AA , Muderspach LI , Brader KR , Morrow CP . A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix . Gynecol Oncol . 2000;76:63–66
  24. Omura GA , Blessing JA , Vaccarello L , Berman ML , Clarke-Pearson DL , Mutch DG , et al.   Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study . J Clin Oncol . 1997;15:165–171
  25. Moore DH , Blessing JA , McQuellon RP , Thaler HT , Cella D , Benda J , et al.   Phase III study of cisplatin with or without paclitaxel in Stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study . J Clin Oncol . 2004;22:3113–3119
  26. Long HJ , Rayson S , Podratz KC , Abu-Ghazaleh S , Suman V , Hartmann LC , et al.   Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature . Am J Clin Oncol . 2002;25:547–551
  27. Long HJ , Bundy BN , Grendys EC , Benda JA , McMeekin DS , Sorosky J , et al.   Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix . J Clin Oncol . 2005;23:4626–4633
  28. Ljubojevic S . The human papillomavirus vaccines . Acta Dermatovenerol Croat . 2006;14:208
  29. Mahdavi A , Monk BJ . Vaccines against human papillomavirus and cervical cancer: promises and challenges . Oncologist . 2005;10:528–538
  30. Bourgault-Villada I . Anti Human-Papillomavirus vaccines: concepts, aims and trials . Rev Med Interne . 2007;28:22–27 [In French]
  31. Birle DC , Hedley DW . Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts . Mol Cancer Ther . 2006;5:2494–2502

PII: S1873-9598(08)70029-2

doi:10.1016/S1873-9598(08)70029-2

International Journal of Gerontology
Volume 1, Issue 2 , Pages 98-102, June 2007

Article Tools